Skip to Main Content

Paper Details

Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer.
Prostate Cancer
0
2022
Author NameAffiliation
Rahul AggarwalHelen Diller Family Comprehensive Cancer Center, University of California San Francisco
Joshi J AlumkalKnight Cancer Institute, Oregon Health and Science University
Joshi J AlumkalRogel Cancer Center, University of Michigan ann arbor
Celestia S HiganoUniversity of Washington, Fred Hutchinson Cancer Research Center
Alan H BryceMayo Clinic Arizona
Eric J SmallHelen Diller Family Comprehensive Cancer Center, University of California San Francisco
  • 1 - 6

Datasets

Release 1.2